A prospective randomized trial of either famotidine or omeprazole for the prevention of bleeding after endoscopic mucosal resection and the healing of endoscopic mucosal resection-induced ulceration.
BACKGROUND
It has been reported that inhibitors of gastric acid secretion prevent bleeding after endoscopic mucosal resection for mucosal gastric neoplasm. However, uncertain whether an histamine2-receptor antagonist or proton-pump inhibitor is more effective.


OBJECTIVE
To evaluate prospectively the effectiveness of famotidine or omeprazole for ulcer management after endoscopic mucosal resection.


METHODS
From July 2003 to October 2004, 57 patients were randomly assigned to famotidine or omeprazole for the management of endoscopic mucosal resection. Both drugs were given intravenously for the first 2 days, thereafter by mouth. The bleeding rates after endoscopic mucosal resection, the effects on the healing of endoscopic mucosal resection-induced ulceration, and cost-benefits were compared.


RESULTS
Twenty-eight patients received famotidine and 29 received omeprazole. No significant difference was observed between the two groups in patient characteristics. The bleeding rates after endoscopic mucosal resection were not significantly different (18% vs. 14%) between the groups. Similarly, no differences were seen in the size of the endoscopic mucosal resection-induced ulceration at 1, 30 and 60 days after resection between groups. The total costs of anti-secretory agents demonstrated a significant cost-benefit to those treated with famotidine (10,420 yen vs. 17,782 yen).


CONCLUSIONS
Famotidine is suggested as a better alternative to omeprazole for the management of endoscopic mucosal resection, as it showed a clear cost-benefit, and the healing results after endoscopic mucosal resection were similar for the two treatment strategies.
Yamaguchi
Y
Y
The Third Department of Internal Medicine, Kyorin University School of Medicine, Mitaka, Tokyo, Japan. yasuharu@kyorin-u.ac.jp
Katsumi
N
N
Tauchi
M
M
Toki
M
M
Nakamura
K
K
Aoki
K
K
Morita
Y
Y
Miura
M
M
Morozumi
K
K
Ishida
H
H
Takahashi
S
S
D000368:Aged; D000897:Anti-Ulcer Agents / Q000191:economics / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D016099:Endoscopy, Gastrointestinal / Q000009:adverse effects* / Q000191:economics; D015738:Famotidine / Q000191:economics / Q000627:therapeutic use*; D005260:Female; D005753:Gastric Mucosa; D006471:Gastrointestinal Hemorrhage / Q000191:economics / Q000517:prevention & control*; D006635:Histamine H2 Antagonists / Q000191:economics / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009853:Omeprazole / Q000191:economics / Q000627:therapeutic use*; D019106:Postoperative Hemorrhage / Q000191:economics / Q000517:prevention & control*; D011446:Prospective Studies; D013274:Stomach Neoplasms / Q000191:economics / Q000601:surgery; D013276:Stomach Ulcer / Q000191:economics / Q000517:prevention & control
D000897:Anti-Ulcer Agents; D006635:Histamine H2 Antagonists; D015738:Famotidine; D009853:Omeprazole